Theravance Biopharma, Inc.
TBPHHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeTheravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. The company carries a $877.5M market cap, placing it firmly in the small-cap category. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
Market Cap
$877.5M
Beta
0.17
P/E (TTM)
7.63
P/E (Fwd)
21.16
EPS (TTM)
$2.22
EPS (Fwd)
$0.80
ROE
50.2%
ROA
0.8%
Cash
$394.7M
Total Debt
$40.5M
Free CF
$22.5M
52W Change
50.5%
Annual Financials
Cash vs Debt
Theravance Biopharma, Inc. holds $394.7M in cash against $40.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $22.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 50.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $51.3M (2022) to $107.5M (2025), reflecting a 109% increase over the period.
The relatively low beta of 0.17 suggests TBPH is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Theravance Biopharma, Inc. and its sector.